Exact Sciences Corporation (NASDAQ:EXAS) Shares Bought by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC grew its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 0.3% in the 1st quarter, HoldingsChannel reports. The firm owned 100,872 shares of the medical research company’s stock after purchasing an additional 270 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Exact Sciences were worth $4,367,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Daiwa Securities Group Inc. raised its position in Exact Sciences by 2.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 14,447 shares of the medical research company’s stock valued at $812,000 after purchasing an additional 300 shares in the last quarter. Integrated Advisors Network LLC raised its holdings in Exact Sciences by 5.7% during the first quarter. Integrated Advisors Network LLC now owns 7,036 shares of the medical research company’s stock worth $305,000 after purchasing an additional 379 shares in the last quarter. Curi RMB Capital LLC raised its stake in Exact Sciences by 1.7% during the 4th quarter. Curi RMB Capital LLC now owns 24,896 shares of the medical research company’s stock worth $1,399,000 after acquiring an additional 428 shares in the last quarter. Patten & Patten Inc. TN lifted its holdings in shares of Exact Sciences by 1.8% in the 4th quarter. Patten & Patten Inc. TN now owns 26,153 shares of the medical research company’s stock valued at $1,470,000 after purchasing an additional 460 shares during the last quarter. Finally, Treasurer of the State of North Carolina boosted its position in shares of Exact Sciences by 0.6% in the 4th quarter. Treasurer of the State of North Carolina now owns 80,216 shares of the medical research company’s stock valued at $4,507,000 after purchasing an additional 500 shares during the period. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Price Performance

Shares of Exact Sciences stock opened at $52.82 on Friday. The company has a current ratio of 2.73, a quick ratio of 2.38 and a debt-to-equity ratio of 0.97. Exact Sciences Corporation has a twelve month low of $39.97 and a twelve month high of $72.83. The stock has a market capitalization of $9.96 billion, a P/E ratio of -9.59, a PEG ratio of 11.39 and a beta of 0.95. The business’s fifty day moving average price is $53.73 and its 200 day moving average price is $51.19.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.16. The firm had revenue of $706.79 million during the quarter, compared to analysts’ expectations of $688.58 million. Exact Sciences had a negative net margin of 36.06% and a negative return on equity of 3.75%. The firm’s revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.60) EPS. As a group, research analysts anticipate that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Insider Activity at Exact Sciences

In related news, Director Katherine S. Zanotti sold 3,207 shares of Exact Sciences stock in a transaction on Friday, June 13th. The shares were sold at an average price of $53.20, for a total transaction of $170,612.40. Following the sale, the director owned 72,759 shares of the company’s stock, valued at $3,870,778.80. The trade was a 4.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Evercore ISI raised their price objective on shares of Exact Sciences from $60.00 to $66.00 and gave the stock an “outperform” rating in a research report on Friday, May 2nd. Mizuho initiated coverage on Exact Sciences in a research report on Thursday, April 10th. They issued an “outperform” rating and a $60.00 price objective for the company. Royal Bank Of Canada lifted their price target on shares of Exact Sciences from $52.00 to $54.00 and gave the company a “sector perform” rating in a research report on Friday, May 2nd. Barclays decreased their price objective on shares of Exact Sciences from $75.00 to $65.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 24th. Finally, Robert W. Baird upped their target price on Exact Sciences from $69.00 to $72.00 and gave the company an “outperform” rating in a research note on Friday, May 2nd. Two analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $70.40.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.